Samira Eshginia1 
, Roghieh Golsha2 , Rahmatollah Sharififar3 , Negar Broumand4 , Fatemeh Mehravar *5
, Roghieh Golsha2 , Rahmatollah Sharififar3 , Negar Broumand4 , Fatemeh Mehravar *5
1- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
2- Infectious Diseases Research Center, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Infectious Diseases, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Surgery, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
5- Ischemic Disorders Research Center, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran ,Mehravar10261@yahoo.com
2- Infectious Diseases Research Center, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Infectious Diseases, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran; Department of Infectious Diseases, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Surgery, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
5- Ischemic Disorders Research Center, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (30 Views)
Background: While vaccines provide substantial protection against COVID-19, breakthrough infections remain a concern. This study aimed to determine the Incidence rate of post-vaccination COVID-19 infections among healthcare workers at teaching hospitals in Gorgan, Northeast Iran between 2020 and 2021.
Methods: In this cross-sectional study, we enrolled all 527 healthcare workers who had received at least one dose of non-mRNA COVID-19 vaccines. Vaccination data were systematically recorded and analyzed. COVID-19 infection was laboratory-confirmed by RT-PCR testing.
Results: The mean age of participants was 35.3±9.8 years. Breakthrough infections occurred in 255 participants (48.4%) after primary vaccination (First and second doses) and in 36 cases (6.83%) following booster doses. Incidence rates were significantly higher among internal medicine and infectious disease staff (p=0.006). Temporal analysis revealed peak infection incidence within 4 months post-primary vaccination, with the lowest rates observed >4 months post-booster administration.
Conclusion: While breakthrough infections occurred in a substantial proportion of participants after primary vaccination, booster doses were associated with significantly lower infection rates. Further research is needed to assess the impact of vaccination status on disease severity.
Methods: In this cross-sectional study, we enrolled all 527 healthcare workers who had received at least one dose of non-mRNA COVID-19 vaccines. Vaccination data were systematically recorded and analyzed. COVID-19 infection was laboratory-confirmed by RT-PCR testing.
Results: The mean age of participants was 35.3±9.8 years. Breakthrough infections occurred in 255 participants (48.4%) after primary vaccination (First and second doses) and in 36 cases (6.83%) following booster doses. Incidence rates were significantly higher among internal medicine and infectious disease staff (p=0.006). Temporal analysis revealed peak infection incidence within 4 months post-primary vaccination, with the lowest rates observed >4 months post-booster administration.
Conclusion: While breakthrough infections occurred in a substantial proportion of participants after primary vaccination, booster doses were associated with significantly lower infection rates. Further research is needed to assess the impact of vaccination status on disease severity.
Keywords: COVID-19, Vaccination, Breakthrough infection, Healthcare workers, Non-mRNA vaccines, Iran
References
1. Biswas N, Mustapha T, Khubchandani J, Price JH. The nature and extent of COVID-19 vaccination hesitancy in healthcare workers. J Community Health. 2021;46(6):1244-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Robilotti EV, Whiting K, Lucca A, Poon C, Jani K, McMillen T, et al. Effectiveness of mRNA booster vaccine among health Care workers in New York City during the omicron surge, December 2021 to January 2022. Clin Microbiol Infect. 2022;28(12):1624-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. Jama. 2021;325(24):2457-65. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-84. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Geysels D, Van Damme P, Verstrepen W, Bruynseels P, Janssens B, Smits P, et al. SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. Infect Control Hosp Epidemiol. 2022;43(11):1755-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Cerqueira-Silva T, de Araújo Oliveira V, Boaventura VS, Pescarini JM, Júnior JB, Machado TM, et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study. Lancet Reg Health Am. 2022;6:100154. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Wang J, Tong Y, Li D, Li J, Li Y. The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:758294 [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Bignucolo A, Scarabel L, Mezzalira S, Polesel J, Cecchin E, Toffoli G. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines. 2021;9(8):825. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet. 2021;397(10275):671-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Eshghinia S, Sharifi Far RA, Hajimoradloo N, Sinesepehr A, Sohrsbi A, Imeri M, et al. The Comparison of Clinical Epidemiology of Hospitalized Patients with COVID-19 during the Third and Fourth Waves of the Pandemic in Gorgan. Can J Infect Dis Med Microbiol. 2022;2022:9634241. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The association between presence of comorbidities and COVID-19 severity: a systematic review and meta-analysis. Cerebrovasc Dis. 2021;50(2):132-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Li C, Li A, Bi H, Hu J, Yang F, Zhou T, et al. Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study. medRxiv. 2022:2022-04. [View at Publisher] [DOI] [Google Scholar]
13. Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother. 2021;53(1):155-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Chandan S, Khan SR, Deliwala S, Mohan BP, Ramai D, Chandan OC, et al. Postvaccination SARS‐CoV‐2 infection among healthcare workers: A systematic review and meta‐analysis. J Med Virol. 2022;94(4):1428-41. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, Ho SB. COVID-19 and healthcare workers: A systematic review and meta-analysis. Int J Infect Dis. 2021;104:335-46. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. bmj. 2022;379:e072065. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Jamaati H, Karimi S, Ghorbani F, Panahi Y, Hosseini‐Baharanchi FS, Hajimoradi M, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran. J Med Virol. 2023;95(3):e28607. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1):22777. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Cucunawangsih C, Wijaya RS, Lugito NP, Suriapranata I. Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia. Int J Infect Dis. 2021;107:268-70. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Crosby JC, Lee RA, McGwin Jr G, Heath SL, Burkholder GA, Gravett RM, et al. A COVID-19 monitoring process for healthcare workers utilizing occupational health. Occup Med. 2024;74(1):71-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Zheng L, Wang X, Zhou C, Liu Q, Li S, Sun Q, et al. Analysis of the infection status of healthcare workers in Wuhan during the COVID-19 outbreak: a cross-sectional study. Clin Infect Dis. 2020;71(16):2109-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Al Maskari Z, Al Blushi A, Khamis F, Al Tai A, Al Salmi I, Al Harthi H, et al. Characteristics of healthcare workers infected with COVID-19: A cross-sectional observational study. Int J Infect Dis. 2021;102:32-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Burgos P, Contreras M, Castro I, Velandia-González M, Salas D, Brustrom J. Protecting our frontline: vaccination policies for health care workers in the Americas. Rev Panam Salud Publica. 2025;49:e102. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Mirahmadizadeh A, Namdar ZM, Miyar A, Maleki Z, Hagheghe LH, Sharifi MH. COVID-19 vaccine acceptance and its risk factors in Iranian health workers 2021. Iran J Med Sci. 2022;47(5):461-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Chaudhary JK, Yadav R, Chaudhary PK, Maurya A, Kant N, Rugaie OA, et al. Insights into COVID-19 vaccine development based on immunogenic structural proteins of SARS-CoV-2, host immune responses, and herd immunity. Cells. 2021;10(11):2949. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
